Upjohn price increases
Prices to wholesalers of the anxiolytic Xanax and hypnotic Halcion raised 7%, representing the second round of price hikes for the two benzodiazepine products this year; in February Upjohn raised prices for the two products by about 14%. In addition, Upjohn is also increasing prices for Micronase and the NSAID Ansaid by 6%. The price increases appear to be a response to flattening sales volume. In the second quarter, Upjohn reported a decline in sales of Xanax, Halcion and Micronase. Corporate sales increased only 2% in the quarter.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.